Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 29;10:29–43. doi: 10.2147/CEOR.S148195

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Ulchaker and Martinson. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Cost-effectiveness simulations of minimally invasive and invasive therapies.

Notes: In 1000 simulated samples of size 100, these figures plot the differences in costs paired with the differences in effectiveness (improvements in IPSS) between two treatments. (A) Prostiva vs Rezūm, (B) UroLift vs Rezūm, (C) TURP vs Greenlight PVP, (D) TURP vs Rezūm, (E) Greenlight PVP vs Rezūm, (F) Rezūmvs ComboRx (generic), and (G) ComboRx (branded) vs Rezūm.

Abbreviations: ComboRx, combination prescription drug therapy; Greenlight^® PVP, photovaporization of the prostate; IPSS, International Prostate Symptom Score; Prostiva^®, conductive radiofrequency thermal therapy; Rezūm^®, convective radiofrequency water vapor thermal therapy; TURP, transurethral resection of the prostate; UroLift^®, prostatic urethral lift.